Clinical Trial Update: 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alternating gemcitabine/nab-paclitaxel and modified FOLFIRINOX in BRCA-related pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Pancreas Adenocarcinoma | Phase 2 | Status: RECRUITING